Lombard Medical Technologies

Lombard Medical Technologies

Lombard Medical Technologies was a UK-based medical device company that designed and commercialized stent-grafts for aortic aneurysm repair. Its primary product was the Aorfix endovascular stent-graft system, which received CE Mark approval in 2004 and FDA approval in 2013. The company targeted physicians treating abdominal aortic aneurysms, aiming to offer a system compatible with challenging anatomy. The company raised over $60M in venture funding from investors including Arpida, MVM Life Science Partners, and Foresight Group. Its strategy centered on direct sales in Europe and a US commercial launch following FDA clearance. Lombard also filed multiple patents related to stent-graft design, including a bifurcated system. By early 2017, the company had incurred significant operating losses and reported annual revenue of approximately $5M. In June 2017, Shanghai-based MicroPort Scientific announced the acquisition of Lombard Medical for an undisclosed sum, valuing the company at a fraction of its cumulative venture investment. The acquisition gave MicroPort access to the Aorfix platform and a US regulatory clearance. Lombard Medical's structural differentiator was its focus on a single product line within a niche of vascular surgery, competing against established giants like Medtronic and Cook Medical. This narrow focus, combined with limited commercialization resources, contributed to its eventual acquisition.